Canagliflozin Should Have Limitations Based On Renal Function, Panel Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Several advisory committee members on both sides of a 10-5 vote voiced concern about using Janssen’s diabetes drug in patients with moderate renal impairment.
You may also be interested in...
FDA Panel To Weigh Dapagliflozin Bladder Cancer, CV Safety Questions
Endocrinologic and Metabolic Drugs Advisory Committee will revisit concerns first discussed at 2011 meeting about bladder cancer risk with Bristol/AstraZeneca’s diabetes drug. Cardiovascular meta-analysis continues to suggest benefit but FDA questions what to make of “discordant” results from two studies in patients with CV disease.
Eyes On Dainippon’s Phase III Stem Cell Cancer Drug – Japan Earnings Profiles
Japan’s earnings season highlights new R&D and launch strategies for Mitsubishi Tanabe, Astellas and Takeda.
Cardiovascular Uncertainty Accompanies Canagliflozin To Advisory Panel
Janssen’s diabetes therapy also will undergo discussions about renal and bone fracture risks during a Jan. 10 meeting of FDA’s Endocrinologic and Metabolic Drugs Advisory Committee.